Potential future dermatological indications for tacrolimus ointment

European Journal of Dermatology

Volumn 13, Issue 4, 2003, Pages 331-342

  Ruzicka, Thomas ^a   Assmann, Till ^a   Lebwohl, Mark ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b MOUNT SINAI HOSPITAL   (United States)

Author keywords

Lichen planus; Lichen sclerosus; Psoriasis; Pyoderma gangrenosum; Tacrolimus

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIMALARIAL AGENT; BETAMETHASONE VALERATE; CALCIPOTRIOL; CLOBETASOL PROPIONATE; CORTICOSTEROID; CYCLOSPORIN A; DITHRANOL; FLUDROXYCORTIDE; FUMARIC ACID; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METRONIDAZOLE; ORABASE; PREDNISOLONE; RETINOID; TACROLIMUS; TETRACYCLINE; UNCLASSIFIED DRUG;

ALOPECIA AREATA; ATOPIC DERMATITIS; BURN; CLINICAL TRIAL; CONTACT DERMATITIS; CROHN DISEASE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOMODULATION; INFLAMMATION; LEG ULCER; LICHEN PLANUS; LICHEN SCLEROSUS ET ATROPHICUS; LYMPHOCYTE ACTIVATION; NONHUMAN; OINTMENT; PRURITUS; PSORIASIS; PUVA; PYODERMA GANGRENOSUM; REVIEW; RHEUMATOID ARTHRITIS; ROSACEA; SKIN ATROPHY; SKIN DISEASE; T LYMPHOCYTE; TREATMENT INDICATION; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; ALOPECIA AREATA; CLINICAL TRIALS; DERMATITIS, CONTACT; DERMATOLOGIC AGENTS; HUMANS; LEG ULCER; LICHEN PLANUS; OINTMENTS; PSORIASIS; PYODERMA GANGRENOSUM; ROSACEA; SKIN DISEASES; TACROLIMUS;

EID: 0042661171     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (104)

1. Fisher DA. Adverse effects of topical corticosteroid use. West J Med 1995; 162: 123-6.
2. Hughes J, Rustin M. Corticosteroids. Clin Dermatol 1997; 15: 715-21.
3. Peter RU, Ruzicka T. Cyclosporin A in the therapy of inflammatory dermatoses. Hautarzt 1992; 43: 687-94.
4. De Rie MA, Meinardi MM, Bos JD. Lack of efficacy of topical cyclosporin A in atopic dermatitis and allergic contact dermatitis. Acta Derm Venereol 1991; 71: 452-4.
5. Surber C, Itin P, Buchner S. Clinical controversy on the effect of topical ciclosporin: what is the target site ? Dermatology 1992; 185: 242-5.
6. Mrowietz U. The enigma of cyclasporin A treatment for psoriasis: systemic efficacy versus topical non-responsiveness. A review. Acta Derm Venereol 1992; 72: 321-6.
7. Faulds D, Goa KL, Benfield P. Cyclosporin. A review of its pharmacodynamic and pharmacakinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 1993; 45: 953-1040.
8. Ruzicka T, Assmann T, Homey B. Tacrolimus: the drug for the turn of the millennium? Arch Dermatol 1999; 135: 574-80.
9. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiol (Tokyo) 1987; 40: 1249-55.
10. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13: 136-42.
11. Liu J, Farmer JD Jr., Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66: 807-15.
12. Meingassner JG, Stutz A. Immunosuppressive macrolides of the type FK 506: a novel class of topical agents for treatment of skin diseases? J Invest Dermatol 1992; 98: 851-5.
13. Lauerma AI, Stein B, Homey B, Lee CH, Bloom E, Maibach HL. Topical FK506 (Tacrolimus): percutaneous absorption and effect on allergic and irritant contact dermatitis. J Invest Dermatol 1993; 100: 491.
14. Alaiti S, Kang S, Fiedler VC, Ellis CN, Spurlin DV, Fader D, et al. Tacrolimus (FK506) ointment for atopic dermotitis: a phase I study in adults and children. J Am Acad Dermatol 1998; 38: 69-76.
15. Reitamo S, Wollenberg A, Schopf E, Perrot JL, Marks R, Ruzicka T, et al. for the European Tacrolimus Ointment Study Group. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol 2000; 136: 999-1006.
16. Panhans-Gross A, Novak N, Kraft S, Bieber T. Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol 2001; 107: 345-52.
17. Wollenberg A, Sharma S, von Bubnoff D, Geiger E, Haberstok J, Bieber T. Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol 2001; 107: 519-25.
18. de Paulis A, Cirillo R, Ciccarelli A, Condorelli M, Marone G. FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI + cells. J Immunol 1991; 146: 2374-81.
19. de Paulis A, Stellato C, Cirillo R, Ciccarelli A, Oriente A, Marone G. Anti-inflammatory effect of FK-506 on human skin mast cells. J Invest Dermatol 1992; 99: 723-8.
20. Remitz A, Kyllönen H, Granlund H, Reitamo S. Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol 2001; 107: 196-7.
21. Pournaras CC, Lubbe J, Saurat JH. Staphylococcal colonization in atopic dermatitis treatment with topical tacrolimus (FK506). J Invest Dermatol 2001; 116: 480-1.
22. Thomson AW, Nalesnik MA, Rilo HR, Woo J, Carroll PB, Van Thiel DH. ICAM-1 and E-selectin expression in lesional biopsies of psoriasis patients responding to systemic FK 506 therapy. Autoimmunity 1993; 15: 215-23.
23. Schulz BS, Michel G, Wagner S, Suss R, Beetz A, Peter RU, et al. Increased expression of epidermal IL-8 receptor in psoriasis. Downregulation by FK-506 in vitro. J Immunol 1993; 151: 4399-406.
24. Lemster BH, Carroll PB, Rilo HR, Johnson N, Nikaein A, Thomson AW. IL-8/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus (FK506) therapy. Clin Exp Immunol 1995; 99: 148-54.
25. Allen BR. Tacrolimus ointment: its place in the therapy of atopic dermatitis. J Allergy Clin Immunol 2002; 109: 401-3.
26. Rico MJ, Lawrence I. Tacrolimus ointment for the treatment of atopic dermatitis: clinical and pharmacologic effects. Allergy Asthma Proc 2002; 23: 191-7.
27. Ruzicka T, Bieber T, Schopf E, Rubins A, Dobozy A, Bos JD, et al., for the European Tacrolimus Multicenter Atopic Dermatitis Study Group. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 1997; 337: 816-21.
28. Hanifin JM, Ling MR, Langley R, Breneman D, Rafal E. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol 2001; 44 (Suppl. 1): S28-38.
29. Soter NA, Fleischer AB Jr., Webster GF, Monroe E, Lawrence I. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol 2001: 44 (Suppl. 1): S39-46.
30. Reitamo S, van Leent EJM, Ho V, Harper J, Ruzicka T, Kalimo K et al., for the European/Canadian Tacrolimus Ointment Study Group. Efficacy and safety of tacrolimus ointment compared with hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 539-46.
31. Reitamo S, Rustin M, Ruzicka T, Cambazard F, Kalimo K, Friedmann PS, et al., for the European Tacrolimus Ointment Study Group. Efficacy and safety of tacrolimus ointment compared with hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 547-55.
32. Reitomo S, Rissanen J, Remitz A, Granlund H, Erkko P, Elg P, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 1998; 111: 396-8.
33. Gawkrodger DJ. Dermatology. 2nd ed. Edinburgh: Churchill Livingstone; 1997. Psoriasis- epidemiology, pathology and presentation, p. 26-7.
34. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1-23.
35. The European FK 506 Multicentre Psoriasis Study Group. Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. Arch Dermatol 1996; 132: 419-23.
36. Zonneveld IM, Rubins A, Jablonska S, Dobozy A, Ruzicka T, Kind P, et al. Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol 1998; 134: 1101-2.
37. Remitz A, Reitamo S, Erkko P, Granlund H, Lauerma AI. Tacrolimus ointment improves psoriosis in a microplaque assay. Br J Dermatol 1999; 141: 103-7.
38. Yamamoto T, Nishioka K. Topical tacrolimus is effective far facial lesions of psoriasis. Acta Derm Venereol 2000; 80: 451.
39. Krupnick A, Linowski GJ, Brady C, Lind L, van Veldhuisen P, Singer G, et al. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. 20th World Congress of Dermatology, Paris, France, 1-5 July 2002: Poster presentation P1990.
40. Bouquot JE, Gorlin RJ. Leukoplakia, lichen planus, and other oral keratoses in 23,616 white Americans over the age of 35 years. Oral Surg Oral Med Orol Pathol 1986; 61: 373-81.
41. Axell T, Rundquist L. Oral lichen planus - a demographic study. Community Dent Oral Epidemiol 1987; 15: 52-6.
42. Banaczy J, Rigo O. Prevalence study of oral precancerous lesions within a complex screening system in Hungary. Community Dent Oral Epidemiol 1991; 19: 265-7.
43. Silverman S Jr. Lozada-Nur F, Migliorati C. Clinical efficacy of prednisone in the treatment of patients with oral inflammatory ulcerative diseases: a study of fifty-five patients. Oral Surg Oral Med Oral Pothol 1985; 59: 360-3.
44. Rozycki TW, Rogers RS 3rd, Pittelkow MR, McEvoy MT, elAzhary RA, Bruce AJ, et al. Topical tacrolimus in the treatment of symptomatic oral lichen planus: a series of 13 patients. J Am Acad Dermatol 2002; 46: 27-34.
45. Kaliakatsou F, Hodgson TA, Lewsey JD, Hegarty AM, Murphy AG, Porter SR. Management of recalcitrant ulcerative oral lichen planus with topical tacrolimus. J Am Acad Dermatol 2002; 46: 35-41.
46. Gadenne AS, Strucke R, Dunn D, Wagner M, Bleicher P, Bigby M. T-cell lines derived from lesional skin of lichen planus patients contain a distinctive population of T-cell receptor gamma delta-bearing cells. J Invest Dermatol 1994; 103: 347-51.
47. Yamamoto T, Nakane T, Osoki T. The mechanism of mononuclear cell infiltration in oral lichen planus: the role af cytokines released from keratinocytes. J Clin Immunol 2000; 20: 294-305.
48. Vente C, Reich K, Rupprecht R, Neumann C. Erosive mucosal lichen planus: response to topical treatment with tacrolimus. Br J Dermatol 1999; 140: 338-42.
49. Lener EV, Brieva J, Schachter M, West LE, West DP, el-Azhary RA. Successful treatment of erosive lichen planus with topical tacrolimus. Arch Dermatol 2001; 137: 419-22.
50. Nazzari G, Cestari R. Tapical tacrolimus ointment in ulcerative lichen planus: an alternative therapeutic approach. Eur J Dermatol 2002; 12: 321.
51. Morrison L, Kratochvil FJ 3rd, Gorman A. An open trial of topical tacralimus for erosive oral lichen planus. J Am Acad Dermatol 2002; 47: 617-20.
52. Olivier V, Lacaur JP, Mousnier A, Garraffa R, Manteil RA, Ortonne JP. Treatment of chronic erosive oral lichen planus with low concentrations of topical tacrolimus: an open prospective study. Arch Dermatol 2002; 138: 1335-8.
53. Callen JP. Pyoderma gangrenosum. Lancet 1998; 351: 581-5.
54. Blitz NM, Rudikoff D. Pyoderma gangrenosum. Mt Sinai J Med 2001; 68: 287-97.
55. Malech HL, Gallin JI. Current concepts: immunology. Neutrophils in human diseases. N Engl J Med 1987; 317: 687-94.
56. Oka M, Berking C, Nesbit M, Satyamoorthy K, Schaider H, Murphy G, et al. Interleukin-8 overexpression is present in pyoderma gangrenosum ulcers and leads ta ulcer farmation in human skin xenografts. Lab Invest 2000; 80: 595-604.
57. Ling MR. Topical tacrolimus ond pimecrolimus: future directions. Semin Cutan Med Surg 2001; 20: 268-74.
58. Schuppe HC, Homey B, Assmann T, Martens R, Ruzicka T. Topical tacrolimus for pyoderma gangrenosum. Lancet 1998; 351: 832.
59. Plettenberg H, Berneburg M, Martens R, Schuppe HC, Ruzicko T, Krutmann J. Topical FK506 in pyodermo gangrenosum. Z Hautkr 2000; 75: 175-6.
60. Reich K, Vente C, Neumann C. Topical tacrolimus for pyoderma gangrenosum. Br J Dermatol 1998; 139: 755-7.
61. Petering H, Kiehl P, Creuer C, Kapp A, Werfel T. Pyoderma gangrenosum: successful topical therapy with tacrolimus (FK506). Hautarzt 2001: 47-50.
62. Lyon CC, Stapleton M, Smith AJ, Mendelsohn S, Beck MH, Griffiths CE. Topical tacrolimus in the management of peristomal pyoderma gangrenosum. J Dermatolog Treat 2001; 12: 13-7.
63. Jolles S, Niclasse S, Benson E. Combination oral and topical tacrolimus in therapy-resistant pyoderma gangrenosum. Br J Dermatol 1999; 140: 564-5.
64. Kimble RM, Tickler AK, Nicholls VS, Cleghorn G. Successful topical tacrolimus (FK506) therapy in a child with pyoderma gangrenosum. J Pediatr Gastroenterol Nutr 2002; 34: 555-7.
65. Marren P, Yell J, Charnock FM, Bunce M, Welsh K, Wojnarowska F. The association between lichen sclerosus and antigens of the HLA system. Br J Dermatol 1995; 132: 197-203.
66. Bousema MT, Romppanen U, Geiger JM, Baudin M, Vaha-Eskeli K, Vartiainen J, et al. Acitretin in the treatment of severe lichen sclerosus et atrophicus of the vulva: a double-blind placebo-controlled study. J Am Acad Dermatol 1994; 30: 225-31.
67. Virgili A, Corazza M, Bianchi A, Mollica G, Califano A. Open study of topical 0.025% tretinoin in the treatment of vulvar lichen sclerosus. One year of therapy. J Reprod Med 1995; 40: 614-8.
68. Assmann T, Ruzicka T. Other potential dermatological indicatians for tacrolimus. In: Ruzicka T, Reitamo S editors. Tacrolimus - a topical immunomodulator for atopic dermatitis. Berlin, Springer; In press.
69. Gawkrodger DJ. Dermatology. 2nd ed. Edinburgh: Churchill Livingstone; 1997. Eczema - basic principles/contact dermatitis, p. 30-1.
70. Lauerma AI, Stein BD, Homey B, Lee CH, Bloom E, Maibach HI. Topical FK506: suppression of allergic and irritant contact dermatitis in the guinea pig. Arch Dermatol Res 1994; 286: 337-40.
71. Lauerma AI, Maibach HI, Granlund H, Erkko P, Kartamaa M, Stubb S. Inhibition of cantact allergy reactions by topical FK506. Lancet 1992; 340: 556.
72. Thurtle OA, Cawley MI. The frequency of leg ulceration in rheumatoid arthritis: a survey. J Rheumatol 1983; 10: 507-9.
73. Pun YL, Barraclough DR, Muirden KD. Leg ulcers in rheumataid arthritis. Med J Aust 1990; 153: 585-7.
74. McRorie ER, Jobanputra P, Ruckley CV, Nuki G. Leg ulceration in rheumatoid arthritis. Br J Rheumatol 1994; 33: 1078-84.
75. Arend WP. The pathophysiology and treatment of rheumatoid arthritis. Arthritis Rheum 1997; 40: 595-7.
76. Espinozo LR, Espinoza CG, Vasey FB, Germain BF. Oral methotrexate therapy for chronic rheumatoid arthritis ulcerations. J Am Acad Dermatol 1986; 15: 508-12.
77. Schuppe H, Richter-Hintz D, Stierle HE, Homey B, Ruzicka T, Lehmann P. Topical tacrolimus for recalcitrant leg ulcer in rheumatoid arthritis. Rheumatology (Oxford) 2000; 39: 105-6.
78. Sneddon I. Adverse effect of topical fluorinated corticasteroids in rosacea. Br Med J 1969; 1: 671-3.
79. Leyden JJ, Thew M, Kligman AM. Steroid rosacea. Arch Dermatol 1974; 110: 619-22.
80. Rapaport MJ, Rapaport V. Eyelid dermatitis to red face syndrome to cure: clinical experience in 100 cases. J Am Acad Dermatol 1999; 41: 435-42.
81. Goldman D. Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report. J Am Acad Dermatol 2001; 44: 995-8.
82. Perret C, Wiesner-Menzel L, Happle R. Immunohistochemical analysis of T-cell subsets in the peribulbar and intrabulbar infiltrates of alopecia areata. Acta Derm Venereol 1984; 64: 26-30.
83. Randall VA. Is alopecia areata an autoimmune disease? Lancet 2001; 358: 1922-4.
84. Meidan VM, Touitou E. Treatments for androgenetic alopecia and alopecia areata: current options and future prospects. Drugs 2001; 61: 53-69.
85. McElwee KJ, Rushton DH, Trachy R, Oliver RF. Topical FK506: a potent immunotherapy for alopecia oreata? Studies using the Dundee experimental bald rat model. Br J Dermatol 1997; 137: 491-7.
86. Freyschmidt-Paul P, Ziegler A, McElwee KJ, Happle R, Kissling S, Sundberg JP, et al. Treatment of alopecia areata in C3H/HeJ mice with the topical immunosuppressant FK506 (Tacrolimus). Eur J Dermatol 2001; 11: 405-9.
87. Yamamoto S, Jiang H, Kato R. Stimulation of hair growth by topical application of FK506, a potent immunosuppressive agent. J Invest Dermatol 1994; 102: 160-4.
88. McMillen R, Duvic M. Alopecia areata occurring in sisters after administration of rifampicin. J Am Acad Dermatol 2001; 44: 142-3.
89. Thiers BH. Topical tacrolimus: treatment failure in a patient with alopecia areata. Arch Dermatol 2000; 136: 124.
90. Mayer K, Reinhard T, Reis A, Bohringer D, Sundmacher R. FK 506 ointment 0.1% - A new therapeutic option for atopic blepharitis. Clinical trial with 14 patients. Klin Monatsbl Augenheilkd 2001; 218: 733-6.
91. Suga Y, Hashimoto Y, Matsuba S, Mizoguchi M, Ogawa H. Topical tacrolimus for chronic actinic dermatitis. J Am Acad Dermatol 2002; 46: 321-3.
92. Uetsu N, Okamoto H, Fujii K, Doi R, Horio T. Treatment of chronic actinic dermatitis with tocrolimus ointment. J Am Acad Dermatol 2002; 47: 881-4.
93. Casson DH, Eltumi M, Tomlin S, Walker-Smith JA, Murch SH. Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease. Gut 2000; 47: 436-40.
94. Hodgson T, Hegarty A, Porter S. Topical tacrolimus and Crohn disease. J Pediatr Gastroenterol Nutr 2001; 33: 633.
95. Russell RK, Richardson N, Wilsan DC. Systemic absorption with complications during topical tacrolimus treatment for orofacial Crohn disease. J Pediatr Gastroenterol Nutr 2001; 32: 207-8.
96. Walker SL, Kirby B, Chalmers RJ. The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus. Br J Dermatol 2002; 147: 405.
97. Krupnick A, Serle J, Van Veldhuisen P, Lind L, Clarke J, Singer G, et al. Tacrolimus ointment for the treatment of eyelid dermatitis. 20th World Congress of Dermatology, Paris, France, 1-5 July 2002: Poster presentation P0266.
98. Di Carlo JB, Braza TJ, McCall CO. An open label pilot study to investigate the efficacy of tacrolimus 0.1% ointment for the treatment of seborrheic dermatitis. 20th World Congress of Dermatology, Paris, France, 1-5 July 2002: Poster presentation P1662.
99. Pauli-Magnus C, Klumpp S, Alscher DM, Kuhlmann U, Mettang T. Short-term efficacy of tacrolimus ointment in severe uremic pruritus. Perit Dial Int 2000; 20: 802-3.
100. Tanghetti EA, Brandt R. Use of tacrolimus in vitiligo. American Academy of Dermatology 60th Annual Meeting. New Orleans, USA, 2-27 February 2002. Poster presentation P516.
101. Grimes PE. Tacrolimus ointment for repigmentation of vitiligo. American Academy of Dermatology 60th Annual Meeting, New Orleans, USA, 2-27 February 2002: Poster presentation P520.
102. Lepe V, Moncada B, Castanedo JP. A double-blind randomized trial of 0.1% tacrolimus versus 0.05% clobetasol for the treatment of childhood vitiligo [abstract]. The Journal of Investigative Dermatology 2002; 119: 342.
103. Soriano T, Grimes PE, Meraz M, Morris R, Avaniss-Aghajoni E, Metzger A. The efficacy and safety of topical tacrolimus in patients with vitiligo. Proceedings of the Society for Investigative Dermatology, 63rd Annual Meeting, Los Angeles, USA, May 15-18 2002: Poster presentation P817.
104. Assmann T, Homey B, Ruzicka T. Applications of tacrolimus for the treatment of skin disorders. Immunopharmacology 2000; 47: 203-13.